Drug
Nal
Nal: highest development phase Phase 3, developed by Trevi Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Trevi Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| NAL ER NCT07868419 | Phase 3 | Idiopathic Pulmonary Fibrosis |
| NAL ER NCT07671911 | Phase 3 | Idiopathic Pulmonary Fibrosis |
Latest
No recent events.
Follow Nal on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.